REVA Medical

Executive Summary

REVA Medical is a San Diego-based medical device company pioneering bioresorbable polymer technologies for vascular applications. Its lead products, the Fantom Encore coronary scaffold and MOTIV peripheral scaffold, are designed to dissolve after restoring blood flow, potentially reducing long-term complications associated with permanent metallic stents. The company has achieved regulatory approval for its platforms and is now focused on commercialization and expanding clinical indications. REVA's technology addresses a significant unmet need in interventional cardiology and peripheral vascular disease, offering a 'leave nothing behind' approach that aligns with evolving physician and patient preferences for bioresorbable devices. With an approved product portfolio and a strong intellectual property position, REVA Medical is well-positioned to capture market share in the growing bioresorbable scaffold segment. The company is expected to accelerate revenue growth through geographic expansion and potential partnerships. Key upcoming catalysts include clinical data readouts for the MOTIV scaffold in peripheral artery disease and progress toward regulatory approvals in additional regions. As a private company, REVA may also attract acquisition interest from larger medical device firms seeking to enter the bioresorbable space. Overall, REVA Medical represents a compelling opportunity in the cardiovascular device market, with a clear pathway to commercialization and multiple near-term value drivers.

Upcoming Catalysts (preview)

• Q3 2026Clinical results from MOTIV peripheral scaffold trial70% success
• Q4 2026CE Mark or other regulatory approval for Fantom Encore in new regions60% success
• TBDStrategic partnership or acquisition interest from larger medtech firms50% success